Professor Paul Hofman receives the Research Award at ISLB 2026 in Madrid.

Liquid Biopsy: Professor Paul Hofman honoured at ISLB 2026 in Madrid

From 7 to 9 November 2026, Professor Paul Hofman, Director of the RespirERA Institute, attended the International Society of Liquid Biopsy (ISLB) Congress in Madrid. As the recipient of the 2026 Research Award, he was recognised for his contributions to liquid biopsy research.

International recognition for his research

The ISLB presented its 2026 Research Award to Professor Paul Hofman, alongside two other recipients honoured in separate categories: Natasha Leighl for clinical research and Evi Lianidou for lifetime achievement. These awards recognise their contributions to liquid biopsy research and the development of its clinical applications.

The eighth edition of the congress brought together researchers, clinicians and diagnostic specialists to discuss scientific advances, technologies and clinical applications in liquid biopsy. It provided a forum for sharing knowledge and examining how these approaches can be integrated into patient care.

Using liquid biopsy to better understand and monitor cancer

A liquid biopsy (a test that analyses a body fluid, usually blood, for material released by a tumour) can detect fragments of DNA shed by cancer cells. Repeated sampling can provide information about a cancer’s characteristics and how they change over time.

In certain advanced lung cancers, this approach helps identify biomarkers (biological characteristics that can guide treatment selection). It can also help detect changes associated with treatment resistance. Liquid biopsy complements tumour tissue analysis, which remains essential for diagnosis and patient management.

Advancing clinical applications through European collaboration

Professor Hofman was also listed in the programme as co-chair of the session on European liquid biopsy research projects, alongside Professor Eloisa Jantus Lewintre. The session brought together the PREDI-LYNCH, SPARC, JA-PCM and GUIDE.MRD initiatives to explore their contributions to developing these approaches and integrating them into healthcare systems.

The aim is to establish the scientific evidence, methods and access needed for wider clinical use of these tests. The participation of the RespirERA Institute’s Director in this session builds on discussions he contributed to at the ISLB workshop in Pompeii in May 2026, which focused on integrating liquid biopsy into laboratories and cancer care pathways.